To investigate how anti-PD-1 treatment affects both Programmed Death-Ligand 1 (PD-L1) expression and glucose metabolism within normal tissues of advanced non-small cell lung cancer (NSCLC) patients using a dual SPECT/CT and PET/CT imaging approach. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.